BACKGROUND: Liver disease is a leading cause of death in human immunodeficiency virus (HIV)-infected women; however, risk factors for hepatitis b virus (hbv) infection in this population have not been well studied. METHODS: We describe the seroprevalence and predictors of HBV infection in a cross-sectional analysis of 2132 women with and at risk for HIV infection enrolled in the Women's Interagency HIV Study during the periods 1994-95 and 2001-02. Any test result positive for antibody to hepatitis B core antigen defined infection; those women with serological evidence of vaccine immunity were excluded from analysis. Women were stratified into those with a history of injection drug use (IDU), those with a history of noninjection drug use (non-IDU), and those with no history of illicit drug use. RESULTS: Of 1606 HIV-infected and 526 HIV-uninfected women, 7% and 12%, respectively, appeared to be vaccine immune. After exclusion of these women, 43% of 1500 HIV-infected and 22% of 461 HIV-uninfected women had HBV infection. HBV infection prevalence differed among the IDU, non-IDU, and no illicit drug use groups (76%, 30%, and 17%, respectively; P<.0001). HBV infection was strongly associated with herpes simplex virus 2 (HSV-2) seropositivity in the IDU group (odds ratio [OR], 2.9; 95% confidence interval [CI], 1.6-5.4) and with a history of syphilis in the non-IDU group (OR, 2.7; 95% CI, 1.4-5.0). DISCUSSION: We found a high prevalence of HBV infection in our cohort of women with and at risk for HIV infection. HSV-2 seropositivity and a history of syphilis appeared to be important correlates of HBV infection. Sexual transmission of HBV, particularly in those with a history of genital ulcer disease, should be a major focus of education in all high-risk groups.
BACKGROUND:Liver disease is a leading cause of death in human immunodeficiency virus (HIV)-infectedwomen; however, risk factors for hepatitis b virus (hbv) infection in this population have not been well studied. METHODS: We describe the seroprevalence and predictors of HBV infection in a cross-sectional analysis of 2132 women with and at risk for HIV infection enrolled in the Women's Interagency HIV Study during the periods 1994-95 and 2001-02. Any test result positive for antibody to hepatitis B core antigen defined infection; those women with serological evidence of vaccine immunity were excluded from analysis. Women were stratified into those with a history of injection drug use (IDU), those with a history of noninjection drug use (non-IDU), and those with no history of illicit drug use. RESULTS: Of 1606 HIV-infected and 526 HIV-uninfectedwomen, 7% and 12%, respectively, appeared to be vaccine immune. After exclusion of these women, 43% of 1500 HIV-infected and 22% of 461 HIV-uninfectedwomen had HBV infection. HBV infection prevalence differed among the IDU, non-IDU, and no illicit drug use groups (76%, 30%, and 17%, respectively; P<.0001). HBV infection was strongly associated with herpes simplex virus 2 (HSV-2) seropositivity in the IDU group (odds ratio [OR], 2.9; 95% confidence interval [CI], 1.6-5.4) and with a history of syphilis in the non-IDU group (OR, 2.7; 95% CI, 1.4-5.0). DISCUSSION: We found a high prevalence of HBV infection in our cohort of women with and at risk for HIV infection. HSV-2 seropositivity and a history of syphilis appeared to be important correlates of HBV infection. Sexual transmission of HBV, particularly in those with a history of genital ulcer disease, should be a major focus of education in all high-risk groups.
Authors: L Rosenblum; W Darrow; J Witte; J Cohen; J French; P S Gill; J Potterat; K Sikes; R Reich; S Hadler Journal: JAMA Date: 1992-05-13 Impact factor: 56.272
Authors: Rajesh T Gandhi; Alysse Wurcel; Barbara McGovern; Hang Lee; Janet Shopis; Colleen P Corcoran; Sarah Toner; Christina Giachetti; Janel Dockter; Paul E Sax; Chinweike Ukomadu Journal: J Acquir Immune Defic Syndr Date: 2003-12-01 Impact factor: 3.731
Authors: Audrey L French; Anna Hotton; Mary Young; Marek Nowicki; Michael Augenbraun; Kathryn Anastos; Eric Seaberg; William Rosenberg; Marion G Peters Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Audrey L French; Eva Operskalski; Marion Peters; Howard D Strickler; Phyllis C Tien; Gerald B Sharp; Marshall J Glesby; Mary Young; Michael Augenbraun; Eric Seaberg; Andrea Kovacs Journal: J Infect Dis Date: 2007-04-05 Impact factor: 5.226
Authors: Audrey L French; Michael Y Lin; Charlesnika T Evans; Lorie Benning; Marshall J Glesby; Mary A Young; Eva A Operskalski; Michael Augenbraun; Marion Peters Journal: Clin Infect Dis Date: 2009-07-01 Impact factor: 9.079
Authors: Helen M Chun; Ann M Fieberg; Katherine Huppler Hullsiek; Alan R Lifson; Nancy F Crum-Cianflone; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; William P Bradley; Brian K Agan; Michael L Landrum Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079
Authors: Mohaned Shilaih; Alex Marzel; Dominique L Braun; Alexandra U Scherrer; Helen Kovari; Jim Young; Alexandra Calmy; Katharine Darling; Manuel Battegay; Matthias Hoffmann; Enos Bernasconi; Maria C Thurnheer; Huldrych F Günthard; Roger D Kouyos Journal: Medicine (Baltimore) Date: 2017-01 Impact factor: 1.889
Authors: Lucy Platt; Clare E French; Catherine R McGowan; Keith Sabin; Erin Gower; Adam Trickey; Bethan McDonald; Jason Ong; Jack Stone; Philippa Easterbrook; Peter Vickerman Journal: J Viral Hepat Date: 2019-12-22 Impact factor: 3.728